Amneal PharmaceuticalsAMRX
About: Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Employees: 8,100
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
156% more call options, than puts
Call options by funds: $3.08M | Put options by funds: $1.2M
105% more repeat investments, than reductions
Existing positions increased: 84 | Existing positions reduced: 41
82% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 22
8% more funds holding
Funds holding: 182 [Q3] → 197 (+15) [Q4]
0% more funds holding in top 10
Funds holding in top 10: 2 [Q3] → 2 (+0) [Q4]
5.43% less ownership
Funds ownership: 46.07% [Q3] → 40.64% (-5.43%) [Q4]
15% less capital invested
Capital invested by funds: $1.18B [Q3] → $997M (-$181M) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
Barclays Balaji Prasad 18% 1-year accuracy 8 / 44 met price target | 49%upside $11 | Overweight Maintained | 3 Mar 2025 |
JP Morgan Chris Schott 29% 1-year accuracy 5 / 17 met price target | 63%upside $12 | Overweight Upgraded | 24 Feb 2025 |
Financial journalist opinion
Based on 5 articles about AMRX published over the past 30 days
